The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience

Basit Öğe Kaydı
dc.authoridAdibelli, Zehra Hilal/0000-0001-9265-8114
dc.authoridDurusoy, Raika/0000-0003-1041-8462
dc.authoridZengel, Baha/0000-0002-1812-6846
dc.authorscopusid57206696792
dc.authorscopusid35184520500
dc.authorscopusid57204535545
dc.authorscopusid57191863721
dc.authorscopusid6507450836
dc.authorscopusid26662535000
dc.authorscopusid57193793819
dc.authorwosidAdibelli, Zehra Hilal/ABE-8234-2020
dc.contributor.authorTercan, Ismail Can
dc.contributor.authorZengel, Baha
dc.contributor.authorOzdemir, Ozlem
dc.contributor.authorCavdar, Demet
dc.contributor.authorTasli, Funda
dc.contributor.authorAdibelli, Zehra Hilal
dc.contributor.authorKaratas, Murat
dc.date.accessioned2024-08-25T18:38:45Z
dc.date.available2024-08-25T18:38:45Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective. To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC). Methods. Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB. Pathologic complete response (ypCR) was defined as the absence of residual invasive and in situ cancer, and near-complete response (ypNCR) represented in situ and/or <= 1 mm residual tumor in the breast and/or presence of malignant cell clusters (& LE;0.2 mm) and/or micrometastases (<= 2.0 mm) in the axillary lymph nodes (ALN) (ypTis/T1mi, ypN0i+/pN1mi). Results. The mean age of the 92 patients was 49.6 +/- 10.3 years and the mean follow-up was 34.0 +/- 17.8 months. With respect to breast tumors, 23 (25.0%) patients had complete and 14 (15.2%) had a near-complete response to NAC. Complete response in ALN was obtained in 39 (42.4%) patients and near-complete in six (6.5%) patients. The overall survival of the 33 patients who achieved ypCR and ypNCR was 100% and the remaining 59 patients with partial or no response to NAC was 83.1% at a mean follow-up of 34 months (p=0.063). Conclusions. In this study, no event developed in cases with ypCR and ypNCR in the breast and axilla. The persistence of the same results in long-termfollow-ups may enable the use of ypNCR as a positive prognostic marker in addition to ypCR.en_US
dc.identifier.doi10.1155/2023/4549033
dc.identifier.issn1075-122X
dc.identifier.issn1524-4741
dc.identifier.pmid36694670en_US
dc.identifier.scopus2-s2.0-85146534821en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1155/2023/4549033
dc.identifier.urihttps://hdl.handle.net/11454/101121
dc.identifier.volume2023en_US
dc.identifier.wosWOS:000922312300001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Hindawien_US
dc.relation.ispartofBreast Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectAdjuvanten_US
dc.subjectTherapyen_US
dc.titleThe Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu